597
Participants
Start Date
October 10, 2022
Primary Completion Date
September 3, 2024
Study Completion Date
September 3, 2024
Tecovirimat Oral Capsule
"200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)"
Placebo
Capsules to match tecovirimat
L'Hôpital Général de Référence de Kole, Kole
L'Hôpital Général de Référence de Tunda, Tunda
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH